Semler Scientific, Inc.

Good afternoon and welcome to the Semler Scientific 2022 fourth quarter and full year financial results conference call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on your telephone keypad. To withdraw your question, please press star then two. Please note this event is being recorded. Before we begin, similar scientific needs to remind you that certain comments made during this call may constitute forward-looking statements, are made pursuant to and within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 as amended. These include statements regarding the expectations for expansion of the business and the development and marketing of additional products, as well as the impact of the CMS advance notice. Such forward-looking statements are subject to both known and unknown risks and uncertainties that could cause actual results to differ materially from such statements. Those risks and uncertainties are described in the press release and our SEC filings. The forward-looking statements made today are as of the date of this call and the company does not undertake any obligation to update the forward-looking statements. If you do not have a copy of today's release, you may obtain one by visiting the investor relations page of the website, SemlerScientific.com. Now, I would like to introduce Doug Murphy-Chatorian, CEO of Semler Scientific.

Good afternoon, everyone, and thank you for joining us for our fourth quarter, 2022, and our full year results call. Today, We announced that I have informed the board that I will be stepping down as CEO and will be assisting to a transition period. I will continue to serve as a member of the board, at least until the remainder of my 2024 term. And I'm pleased to announce that Dr. Wayne Pan will see me as CEO effective April 3rd, 2023. Wayne has served as a member of the board since May of 2014, has broad healthcare experience and confident that he will be able to lead the company into the next phase of growth and continue to make a difference every day for our customers and the patients we serve. It has been an honor to lead the team, and I'm proud of the business we built together. First quarter 2023 guidance in terms of revenue represents the highest quarterly revenue that Semler has achieved in this century. So without further ado, I want to introduce you to Dr. Pan. Wayne?

Thank you, Doug. On behalf of the board, I'd like to thank Doug for his commitment and notable contributions to Semler over the past 12 years. He's been instrumental in the evolution of the company, and I look forward to continuing to work with him as a member of our board. And I'm very grateful for the opportunity to serve as CEO of Semler Scientific and lead the company into its next phase of growth. I believe Semler has diagnostic tools that will unlock a new paradigm in cardiovascular care, as well as create value for our stockholders. Our products will increase access, promote health equity, and enable earlier diagnosis of progressive diseases that affect millions of people globally. Semla will be presenting and hosting one-on-one meetings at the Needham Virtual Healthcare Conference on April 18th, 2023. Well, I look forward to laying out my vision and meeting with the investor community. I'll now hand the call over to Renee.